Inflammatory and functional effects of increasing asthma treatment with formoterol or double dose budesonide

Respiratory Medicine

Volumn 102, Issue 10, 2008, Pages 1385-1391

  Menezes, Marcelo B ^a   Teixeira, Antônio L ^b   Filho, João Terra ^a   Vianna, Elcio O ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Adrenergic beta agonists; Asthma; Budesonide; Cell cultures; Eosinophils; Peak expiratory flow rate

Indexed keywords

BUDESONIDE; EOTAXIN 2; FORMOTEROL; INTERLEUKIN 4; SALBUTAMOL; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; ASTHMA; CELL COUNT; CELL CULTURE; CELL VIABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; INFLAMMATION; LUNG FUNCTION TEST; MALE; NEUTROPHIL COUNT; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; SPUTUM CULTURE; STATISTICAL SIGNIFICANCE; SYMPTOM; TREATMENT DURATION;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ADULT; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; CYTOKINES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; GLUCOCORTICOIDS; HUMANS; LUNG; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; TREATMENT FAILURE;

EID: 50249086307     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2008.04.022     Document Type: Article

References (37)

1. National Heart LaBI, World Health Organization. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. National Institute of Health NHLBI/WHO Workshop Report 2006;1-110.
2. Barnes P.J., Pedersen S., and Busse W.W. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 157 3 Pt 2 (1998) S1-S53
3. Greening A.P., Ind P.W., Northfield M., and Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 344 8917 (1994) 219-224
4. Jenkins C., Woolcock A.J., Saarelainen P., Lundback B., and James M.H. Salmeterol/fluticasone propionate combination therapy 50/250 microg twice daily is more effective than budesonide 800 microg twice daily in treating moderate to severe asthma. Respir Med 94 7 (2000) 715-723
5. van Noord J.A., Schreurs A.J., Mol S.J., and Mulder P.G. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax 54 3 (1999) 207-212
6. Woolcock A., Lundback B., Ringdal N., and Jacques L.A. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 153 5 (1996) 1481-1488
7. Li X., Ward C., Thien F., Bish R., Bamford T., Bao X., et al. An anti-inflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med 160 5 Pt 1 (1999) 1493-1499
8. Pace E., Gagliardo R., Melis M., La Grutta S., Ferraro M., Siena L., et al. Synergistic effects of fluticasone propionate and salmeterol on in vitro T-cell activation and apoptosis in asthma. J Allergy Clin Immunol 114 5 (2004) 1216-1223
9. Usmani O.S., Ito K., Maneechotesuwan K., Ito M., Johnson M., Barnes P.J., et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med 172 6 (2005) 704-712
10. Wallin A., Sue-Chu M., Bjermer L., Ward J., Sandstrom T., Lindberg A., et al. Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma. J Allergy Clin Immunol 112 1 (2003) 72-78
11. Nelson H.S., Weiss S.T., Bleecker E.R., Yancey S.W., and Dorinsky P.M. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129 1 (2006) 15-26
12. Boulet L.P., Chakir J., Milot J., Boutet M., and Laviolette M. Effect of salmeterol on allergen-induced airway inflammation in mild allergic asthma. Clin Exp Allergy 31 3 (2001) 430-437
13. McIvor R.A., Pizzichini E., Turner M.O., Hussack P., Hargreave F.E., and Sears M.R. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 158 3 (1998) 924-930
14. Pizzichini M.M., Kidney J.C., Wong B.J., Morris M.M., Efthimiadis A., Dolovich J., et al. Effect of salmeterol compared with beclomethasone on allergen-induced asthmatic and inflammatory responses. Eur Respir J 9 3 (1996) 449-455
15. Paggiaro P.L., Chanez P., Holz O., Ind P.W., Djukanovic R., Maestrelli P., et al. Sputum induction. Eur Respir J Suppl 37 (2002) 3s-8s
16. Anderson S.D., and Brannan J.D. Methods for "indirect" challenge tests including exercise, eucapnic voluntary hyperpnea, and hypertonic aerosols. Clin Rev Allergy Immunol 24 1 (2003) 27-54
17. Riedler J., and Robertson C.F. Effect of tidal volume on the output and particle size distribution of hypertonic saline from an ultrasonic nebulizer. Eur Respir J 7 5 (1994) 998-1002
18. Lalloo U.G., Malolepszy J., Kozma D., Krofta K., Ankerst J., Johansen B., et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild to moderate asthma. Chest 123 5 (2003) 1480-1487
19. Van Schoor J., Joos G.F., and Pauwels R.A. Indirect bronchial hyperresponsiveness in asthma: mechanisms, pharmacology and implications for clinical research. Eur Respir J 16 3 (2000) 514-533
20. Anderson S.D., du Toit J.I., Rodwell L.T., and Jenkins C.R. Acute effect of sodium cromoglycate on airway narrowing induced by 4.5 percent saline aerosol. Outcome before and during treatment with aerosol corticosteroids in patients with asthma. Chest 105 3 (1994) 673-680
21. du Toit J.I., Anderson S.D., Jenkins C.R., Woolcock A.J., and Rodwell L.T. Airway responsiveness in asthma: bronchial challenge with histamine and 4.5% sodium chloride before and after budesonide. Allergy Asthma Proc 18 1 (1997) 7-14
22. Rodwell L.T., Anderson S.D., and Seale J.P. Inhaled steroids modify bronchial responses to hyperosmolar saline. Eur Respir J 5 8 (1992) 953-962
23. Kips J.C., O'Connor B.J., Inman M.D., Svensson K., Pauwels R.A., and O'Byrne P.M. A long-term study of the anti-inflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med 161 3 Pt 1 (2000) 996-1001
24. Jarjour N.N., Wilson S.J., Koenig S.M., Laviolette M., Moore W.C., Davis W.B., et al. Control of airway inflammation maintained at a lower steroid dose with 100/50 microg of fluticasone propionate/salmeterol. J Allergy Clin Immunol 118 1 (2006) 44-52
25. Busse W.W., Chervinsky P., Condemi J., Lumry W.R., Petty T.L., Rennard S., et al. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol 101 4 Pt 1 (1998) 457-463
26. Holt S., Suder A., Weatherall M., Cheng S., Shirtcliffe P., and Beasley R. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ 323 7307 (2001) 253-256
27. Masoli M., Weatherall M., Holt S., and Beasley R. Clinical dose-response relationship of fluticasone propionate in adults with asthma. Thorax 59 1 (2004) 16-20
28. Jeffery P.K., Venge P., Gizycki M.J., Egerod I., Dahl R., and Faurschou P. Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study. Eur Respir J 20 6 (2002) 1378-1385
29. Maneechotesuwan K., Essilfie-Quaye S., Meah S., Kelly C., Kharitonov S.A., Adcock I.M., et al. Formoterol attenuates neutrophilic airway inflammation in asthma. Chest 128 4 (2005) 1936-1942
30. Bettiol J., Sele J., Henket M., Louis E., Malaise M., Bartsch P., et al. Cytokine production from sputum cells after allergenic challenge in IgE-mediated asthma. Allergy 57 12 (2002) 1145-1150
31. Boniface S., Koscher V., Mamessier E., El Biaze M., Dupuy P., Lorec A.M., et al. Assessment of T lymphocyte cytokine production in induced sputum from asthmatics: a flow cytometry study. Clin Exp Allergy 33 9 (2003) 1238-1243
32. Hamzaoui A., Brahim M.B., Zhioua A., Ayed K., and Hamzaoui K. Inflammatory response in induced sputum mononuclear cells from patients with acute exacerbation of asthma. Mediators Inflamm 9 3-4 (2000) 147-153
33. Komai-Koma M., McKay A., Thomson L., McSharry C., Chalmers G.W., Liew F.Y., et al. Immuno-regulatory cytokines in asthma: IL-15 and IL-13 in induced sputum. Clin Exp Allergy 31 9 (2001) 1441-1448
34. Liu L.Y., Swensen C.A., Kelly E.A., Kita H., and Busse W.W. The relationship of sputum eosinophilia and sputum cell generation of IL-5. J Allergy Clin Immunol 106 6 (2000) 1063-1069
35. Quaedvlieg V., Henket M., Sele J., and Louis R. Cytokine production from sputum cells in eosinophilic versus non-eosinophilic asthmatics. Clin Exp Immunol 143 1 (2006) 161-166
36. Scheicher M.E., Teixeira M.M., Cunha F.Q., Teixeira Jr. A.L., Filho J.T., and Vianna E.O. Eotaxin-2 in sputum cell culture to evaluate asthma inflammation. Eur Respir J 29 3 (2007) 489-495
37. Kankaanranta H., Lindsay M.A., Giembycz M.A., Zhang X., Moilanen E., and Barnes P.J. Delayed eosinophil apoptosis in asthma. J Allergy Clin Immunol 106 1 Pt 1 (2000) 77-83